leadf
logo-loader
viewANGLE PLC

ANGLE PLC's Andrew Newland updates as blood donations restart to support its key studies

ANGLE PLC's (LON:AGL, OTCQX:ANPCY) Andrew Newland speaks to Proactive London after announcing blood donations have restarted to support its US Food & Drug Administration analytical studies, while patient enrolment to its ovarian cancer test has also recommenced.

Newland says he's hoping to complete the work required for the FDA submission in the third quarter subject to the uncertainties caused by the coronavirus lockdown.

Quick facts: ANGLE PLC

Price: 43.5 GBX

AIM:AGL
Market: AIM
Market Cap: £93.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read